Irinotecan (camptothecin-11 (
CPT-11)) is a topoisomerase I inhibitor that has been used in the treatment of a wide spectrum of cancer, particularly colorectal cancer.
[10] (2008) DTX [right arrow] PTX [right arrow]
CPT-11 Tanizaki et al.
[7] Saitoh- CDDP,
CPT-11 ANED, 12 Mo Sekiguchi et al.
A phase II study of
CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
Irinotecan (
CPT-11) is a camptothecin-derived cytotoxic anticancer drug.
Two clinically used CPT derivatives irinotecan (
CPT-11) and topotecan are widely used to inhibit the growth of lung cancer in combination with cisplatin, paclitaxel [9], and bevacizumab [10].
Initially, the collaboration will concentrate on the development of next-generation product candidate to TheraBiologics' TBX02, which uses an established NSC line engineered to express a modified carboxylesterase enzyme that converts the prodrug,
CPT-11 (Irinotecan), to the potent chemotherapy agent, SN-38, which is 1000x more toxic to cancer cells than
CPT-11.
Establishment of a camptothecin analog (
Cpt-11)-resistant cell-line of human non-small cell lung-cancer--characterization and mechanism of resistance.
Including acetaminophen and the chemotherapy medication
CPT-11. The authors propose that the same mechanisms may be at work with environmental chemicals.
Pharmacology of topoisomerase I inhibitors irinotecan (
CPT-11) and topotecan.
A retrospective study of bifractionated
CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and
CPT-11 containing chemotherapies
Colorectal cancer patients were treated with oxaliplatin plus 5-fluorouracil (5-FU), or weekly
CPT-11 or 5-FU and folates (FA).
